0000950170-24-000450.txt : 20240102
0000950170-24-000450.hdr.sgml : 20240102
20240102200613
ACCESSION NUMBER: 0000950170-24-000450
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240101
FILED AS OF DATE: 20240102
DATE AS OF CHANGE: 20240102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jacques Rachelle Suzanne
CENTRAL INDEX KEY: 0001772610
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36288
FILM NUMBER: 24504088
MAIL ADDRESS:
STREET 1: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
STREET 2: 100 RIVER RIDGE DRIVE
CITY: NORWOOD
STATE: MA
ZIP: 02062
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akari Therapeutics Plc
CENTRAL INDEX KEY: 0001541157
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981034922
STATE OF INCORPORATION: X0
BUSINESS ADDRESS:
STREET 1: 22 BOSTON WHARF ROAD
STREET 2: FL 7
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (646) 350-0702
MAIL ADDRESS:
STREET 1: 22 BOSTON WHARF ROAD
STREET 2: FL 7
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Celsus Therapeutics Plc.
DATE OF NAME CHANGE: 20130621
FORMER COMPANY:
FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC
DATE OF NAME CHANGE: 20120201
3
1
ownership.xml
3
X0206
3
2024-01-01
0
0001541157
Akari Therapeutics Plc
AKTX
0001772610
Jacques Rachelle Suzanne
C/O AKARI THERAPEUTICS, PLC
22 BOSTON WHARF ROAD FL 7
BOSTON
MA
02210
true
true
false
false
Chief Executive Officer
Ordinary Shares, par value $0.0001 per share
538457900
D
Stock Option (Right to Buy)
0.0124
2032-06-01
Ordinary Shares, par value $0.0001 per share
207634400
D
Stock Option (Right to Buy)
0.0124
2032-07-29
Ordinary Shares, par value $0.0001 per share
29762300
D
Stock Option (Right to Buy)
0.0016
2023-06-01
2033-06-01
Ordinary Shares, par value $0.0001 per share
152690700
D
Securities beneficially owned totaling 538,457,900 includes 153,397,775 ordinary shares, par value $0.0001per share ("Ordinary Shares") owned and 385,060,125 of unvested time-based restricted stock units held by the Reporting Person.
The stock option award was granted under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on March 28, 2022, subject to continued service with the Issuer.
The stock option award was granted under the Issuer's 2014 Plan. The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on June 1, 2023, subject to continued service with the Issuer.
/s/ Rachelle Jacques
2024-01-02